Ulster Society of Gastroenterology Logo

‘Missed’ oesophageal adenocarcinoma and high grade dysplasia in Barrett’s oesophagus patients: a large population-based study

Authors

van Putten M, Johnston BT, Murray LJ, Gavin AT, McManus DT, Bhat S, Turkington RC, Coleman HG.

Departments / Institutions

a Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, the Netherlands. b Department of Gastroenterology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland. c Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland d Northern Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland e Department of Pathology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland. f Department of Gastroenterology, Craigavon Area Hospital, Southern Health and Social Care Trust, Belfast, Northern Ireland. g Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland

Publication Date

Autumn 2016

Aims

A recent systematic review suggests that 25% of oesophageal adenocarcinomas (OAC) developing in Barrett’s oesophagus (BO) patients are ‘missed’ at index endoscopy, however more population-based data are needed.

Methods

A recent systematic review suggests that 25% of oesophageal adenocarcinomas (OAC) developing in Barrett’s oesophagus (BO) patients are ‘missed’ at index endoscopy, however more Patients from the Northern Ireland BO register diagnosed between 1993-2010 were selected (n=13,159). Linkage to the Northern Ireland Cancer Registry identified patients who developed OAC or high-grade dysplasia (HGD) by end 2013. The main outcome was the proportion of HGD/OAC diagnosed within 3-12 months following BO diagnosis (potential ‘missed’ cases). Logistic regression analysis compared characteristics of ‘missed’ versus ‘incident’ HGD/OAC occurring after one year after incident BO.population-based data are needed.

Results

There were 267 patients diagnosed with HGD/OAC at least three months after BO diagnosis, of which 34 patients (12.7%) were potential ‘missed’ cases. The proportion of ‘missed’ HGD/OAC increased to 25% within patients with lowgrade dysplasia (LGD) compared to 9% of non-dysplastic BO patients. Older age carried a higher risk of ‘missed’ compared with incident HGD/OAC. Non-dysplastic BO patients were more likely to be detected with a ‘missed’ OAC (rather than HGD), compared with BO-LGD patients (89 v. 40% of ‘missed’ progression detected as OAC, respectively).

Conclusion

HGD/OAC may be ‘missed’ at index BO endoscopy in up to 13% of BO patients and 9% of non-dysplastic BO patients who progressed to HGD/OAC, which is significant but substantially lower than previously reported estimates. Higher rates of ‘missed’ HGD/OAC in LGD-BO likely reflect appropriate surveillance. Increased awareness, adequate biopsy sampling and identifying biomarkers may reduce the number of ‘missed’ cases.


Latest Event

USG Autumn Meeting 2021

Event takes place on October 14, 2021

E-Publications

Download our latest Documents

USGE Membership

Members of the USGE may login below to access the full site.

Selected Abstracts from our Database